ImmunoTEP for Patients With Medullary Thyroid Carcinoma. (iTEP-CMT)
|ClinicalTrials.gov Identifier: NCT01730638|
Recruitment Status : Completed
First Posted : November 21, 2012
Last Update Posted : January 19, 2017
|Condition or disease||Intervention/treatment||Phase|
|Medullary Thyroid Carcinoma||Drug: • TF2 and 68 Ga-IMP-288||Phase 1 Phase 2|
Variation of TF2 molar dose, IMP-288 molar dose and pretargeting interval will be performed in 4 to 5 cohorts of 3 patients, receiving 30 to 120 nmol of TF2 and 1.5 to 6 nmol of peptides 1 to 3 days apart. Blood samples will be obtained after TF2 and 68Ga-IMP-288 injections.
A last cohort (cohorte number 5 or 6) with optimal conditions will be proposed. Whole-body PET images will be recorded 60 and 120 minutes after 68Ga-IMP-288 injection to assess semi-quantitatively tumor targeting and tumor/background ratio. Moreover, the targeting sensitivity of the TF2-pretargeted 68Ga-IMP-288 will be compared to standard methods of tumor.
some patient will have a second immuno-TEP for their follow up in the first examen was the most sensible.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.|
|Study Start Date :||January 2013|
|Primary Completion Date :||December 2016|
|Study Completion Date :||December 2016|
Drug: • TF2 and 68 Ga-IMP-288
- • TF2: trivalent recombinant humanized antibody recognizing the ACE and the peptide histamine-succinyl-glycine IMP-288 (HSG)
- • 68 Ga-IMP-288: di-HSG peptide-DOTA-labeled with Gallium 68
- Evaluation of the tumor targeting (No Unit) and signal/noise (No Unit)ratio by immunoTEP with TF2 and 68-Ga-IMP-288 [ Time Frame: one week ]
Decrease of TF2 and IMP- 288 molar doses and variation of pretargeting interval will be performed in 4 to 5 cohorts of 3 patients, receiving 120 to 30 nmol of TF2 and 6 à 1.5 nmol of peptides 1 to 3 days apart.
A last cohort (number 5 or 6) with optimal conditions will be proposed Blood samples will be obtained after TF2 and 68Ga-IMP-288 injections. Whole-body PET images will be recorded 60 to 120 minutes after 68Ga-IMP-288 injection to assess semiquantitatively tumor targeting and tumor/background ratio.
- Sensibilité [ Time Frame: 6 monts after immunoTEP ]
- tolerance [ Time Frame: 6 monts after immunoTEP ]
- a second _iTEP if necessary for the follow up of a lesion [ Time Frame: 6 monts after immunoTEP ]with in the follow up of the pateint
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01730638
|Angers, France, 49100|
|Nantes, France, 44100|
|Institut de Cancérologie de l'ouest, René Gauducheau|
|Sant Herblain, France, 44805|
|Principal Investigator:||Francoise Bodere, PhD, MD||Nantes Hospital|